International Clinical Trial: 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer

Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07779694) titled '16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer' on Aug. 18.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Zhejiang University

Condition: pMMR/MSS Locally Advanced Rectal Carcinoma Fasting, Intermittent

Intervention: Behavioral: 16-Hour Fasting

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 1, 2026

Target Sample Size: 51

To know more, visit https://clinicaltrials.gov/study...